Skip to content

Amgen

Recent events

Recent events tied to this brand in public sources.

Back to profile49 entries · Page 1 of 3

  1. 2026

    France recalls Tavneos batches after deaths linked in Japan

    France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.

  2. 2024

    Sandoz and Amgen settle US denosumab patent disputes

    Sandoz announced an agreement with Amgen resolving patent disputes concerning Sandoz's FDA-approved denosumab biosimilars. The agreement permits Sandoz to enter the US market with biosimilar versions of Prolia and Xgeva on May 31, 2025, or earlier under specified circumstances.

  3. 2024

    Amgen sues over state drug price cap

    Amgen sued the state over the Prescription Drug Affordability Board’s decision to cap the price of Enbrel. The report says Amgen believes the law permitting the cap is unconstitutional and conflicts with federal law.

  4. 2024

    Amgen sues Colorado over drug price board

    Amgen filed a lawsuit against Colorado over the state Prescription Drug Affordability Board’s actions concerning Enbrel, arguing that the board’s actions are unconstitutional and seeking to overturn decisions about the drug and strike down parts of the law establishing the board.

  5. 2024

    Amgen sues Colorado drug affordability board

    Amgen and two subsidiaries filed a lawsuit in U.S. District Court in Denver alleging that the Colorado law creating the Prescription Drug Affordability Board is unconstitutional and should be overturned. The suit challenges the board's finding that Enbrel is unaffordable.

  6. 2023

    FDA approves Amgen's WEZLANA

    On October 31, the FDA approved Amgen's WEZLANA as a biosimilar to and interchangeable with Janssen's STELARA. The article identifies WEZLANA as the first product approved as a biosimilar to STELARA.

  7. 2023

    Amgen completes acquisition of Horizon Therapeutics

    Amgen announced that it completed its acquisition of Horizon Therapeutics for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

  8. 2023

    Generate:Biomedicines raises $273 million in Series C financing

    Generate:Biomedicines announced that it raised $273 million in Series C financing. The company said it would use the funds to advance its pipeline and validate and improve its AI platform.

  9. 2023

    FTC sues to block Amgen's acquisition of Horizon Therapeutics

    The U.S. Federal Trade Commission filed a lawsuit to stop Amgen's proposed $27.8 billion acquisition of Horizon Therapeutics. The FTC said it was concerned Amgen could use its leading drugs to pressure insurers and pharmacy benefit managers to grant favorable terms for Horizon products. Amgen said it was disappointed and disputed that the deal raised legitimate competitive issues.

  10. 2023

    Amgen sues Sandoz and Novartis over proposed biosimilars

    Amgen sued Novartis's Sandoz in New Jersey federal court, accusing Sandoz's proposed biosimilars of Prolia and Xgeva of infringing patents. Amgen asked the court to block the biosimilars until its patents expire; the allegations are not presented as a court determination.

  11. 2023

    Amgen sues Novartis and Sandoz over proposed biosimilars

    Amgen sued Novartis and its Sandoz business in federal court in New Jersey, accusing Sandoz's proposed versions of Prolia and Xgeva of infringing patents. Amgen asked the court to block the biosimilars until its patents expire.

  12. 2022

    Amgen announces acquisition of Horizon Therapeutics

    Amgen announced that it would acquire Horizon Therapeutics in a transaction valued at approximately $26.4 billion.

  13. 2022

    Amgen Thailand earns Great Place to Work certification

    Amgen Thailand announced that it received Great Place to Work certification for 2022–2023 following an independent audit.

  14. 2022

    Inversago Pharma completes Series C financing

    Inversago Pharma announced completion of a CAD 95 million Series C financing led by New Enterprise Associates, with additional new investors Forbion Growth Opportunities Fund and Amgen Ventures joining existing investors.

  15. 2022

    Amgen agrees to acquire ChemoCentryx

    Amgen announced an agreement to acquire ChemoCentryx in a cash transaction valued at approximately $3.7 billion, including the acquisition of ChemoCentryx's Tavneos treatment. The transaction was subject to customary closing conditions, stockholder approval and regulatory approvals, and was expected to close in the fourth quarter of 2022.

  16. 2022

    IDEAYA and Amgen enter clinical trial collaboration

    IDEAYA announced a clinical trial collaboration and supply agreement with Amgen to evaluate IDE397 in combination with Amgen's AMG 193 in a Phase 1 clinical trial. Amgen will sponsor the trial, and the companies will share external costs and jointly oversee development of the combination therapy.

  17. 2022

    FDA approves RIABNI for rheumatoid arthritis

    Amgen announced that the FDA approved RIABNI, in combination with methotrexate, for adults with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more tumor necrosis factor antagonist therapies.

  18. 2022

    Amgen named recipient of LUNGevity Hope Award for Corporate Leadership

    LUNGevity Foundation announced Amgen as the recipient of its 2022 Hope Award for Corporate Leadership. The award is scheduled to be presented at LUNGevity's annual NY Celebration of Hope Gala in November.

  19. 2022

    Lindis Biotech sues Amgen over patents

    Lindis Biotech filed a complaint against Amgen in the District of Delaware, alleging that Amgen infringed three patents relating to an immunotherapy regimen. The complaint seeks a declaration of infringement and damages, among other relief; the allegations are not presented as a court determination.

  20. 2021

    FDA approves Tezspire for severe asthma

    The U.S. Food and Drug Administration approved Tezspire, developed by Amgen and AstraZeneca, as add-on maintenance treatment for adult and pediatric patients aged 12 years and older with severe asthma.